Lichen Planopilaris

Clinical guidelines for managing primary cicatricial scarring alopecia, evaluating follicular stem cell damage, and reviewing local steroids, Hydroxychloroquine, and JAK inhibitors.

⏱️ 4 min read

Table of Contents

🧠 Standard of Care & Symptoms

Lichen Planopilaris (LPP) is a primary lymphocytic cicatricial (scarring) alopecia that results in permanent, irreversible hair loss.

🧬 Diagnostics & Bulge Stem Cell Attack

Diagnosis requires a detailed trichoscopic evaluation and confirmation via a scalp punch biopsy of an active margin.

Pathogenesis & Bulge Stem Cell Destruction

The permanent nature of LPP hair loss is due to targeted autoimmune destruction of the regenerative machinery:

πŸ’Š Corticosteroids, Hydroxychloroquine & JAK Blockade

Therapy focuses on halting the inflammatory progression and preserving existing hair. Regrowth of already scarred patches is not possible.

First-Line Local Therapy

Systemic Maintenance Therapy

Systemic JAK Inhibitors (Refractory/Rapid Cases)

πŸ”¬ Active Clinical Trials

Clinical trials are currently evaluating selective JAK-1/3 inhibitors, low-dose oral naltrexone as an anti-inflammatory adjunct, and platelet-rich plasma (PRP) injections to stabilize tissue microenvironments.

NCT06922655: Oral Baricitinib (JAK1/JAK2 Inhibitor) for LPP and FFA

A randomized controlled trial testing the efficacy of baricitinib in halting scalp inflammation and follicular scarring.

Key Inclusion: Age 18 to 70, biopsy-confirmed active classic Lichen Planopilaris or Frontal Fibrosing Alopecia, with baseline LPP Activity Index (LPPAI) ≥ 4.
NCT07050456: Low-Dose Oral Naltrexone for Scalp Pruritus and Inflammation

Evaluating whether low-dose naltrexone downregulates glial cell activation and microglial inflammation to reduce scalp pain and itch.

Key Inclusion: Age ≥ 18, active symptomatic LPP, experiencing moderate to severe scalp pain or itching.
NCT07119455: Platelet-Rich Plasma (PRP) vs. Intralesional Steroids

Comparing the anti-inflammatory and tissue healing outcomes of autologous PRP infusions versus triamcinolone injections.

Key Inclusion: Age 18 to 65, active classic LPP, displaying perifollicular scale.
Important: Browse actively recruiting clinical trials in our Clinical Trials Catalogue to find a local study.

πŸ—ΊοΈ Next Steps After Diagnosis

If you have recently been diagnosed with Lichen Planopilaris, coordinate these care pathways:

  1. Perform a Scalp Biopsy: Confirm that the hair loss is a lymphocytic scarring form (LPP) rather than a non-scarring form like alopecia areata.
  2. Initiate Local Steroids: Start clobetasol ointment or schedule intralesional steroid injections to immediately cool down active inflammation.
  3. Discuss Hydroxychloroquine: If inflammation is widespread or spreading, consult your dermatologist about starting hydroxychloroquine (requires baseline eye exam).
  4. Avoid Scalp Trauma: Avoid harsh chemical treatments, tight hairstyles, or heavy heat tools, which can accelerate follicle loss.

❓ Patient FAQ

Q: Will my hair grow back in the areas where it has been lost?
A: Unfortunately, no. In Lichen Planopilaris, the immune system destroys the stem cells in the **follicular bulge**, which are required to grow new hair. Once these cells are destroyed, the hair follicle is permanently replaced by scar tissue. The goal of all LPP treatments is to save the hair you currently have by halting the spread of the disease; they cannot restore hair in patches that are already smooth and scarred.

Q: How long does it take for treatments to start working?
A: LPP is a slow-moving but persistent disease, and treatments take time to stabilize the immune system. Systemic medications like Hydroxychloroquine typically require 3 to 6 months of daily use before you will notice a reduction in scalp itching, burning, or hair shedding. It is vital to continue your medications consistently even if you do not see immediate improvement.

Get the Free 2026 Clinical AI Directory

Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.

Request Directory via Email